Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Deleobuvir in Healthy Males
NCT02182388Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2007
- Primary completion
- May 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of deleobuvir in hepatitis C (HCV) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with abnormal findings in physical examination, Number of patients with clinically significant changes in vital signs and 4 more. Started Jan 2007; status: completed.
02
Drugs
deleobuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02182388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182388.